Skip to content
Biodatica
Start free

Janssen Pharmaceutica N.V., Belgium

Kiel

OncologyPhase IListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    EARLY_PHASE1 registered

    Oct 31, 2022

    Hepatitis B, Chronic · WITHDRAWN · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

    ClinicalTrials.gov · NCT05550519 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Nov 18, 2021

    Relapsed/Refractory Multiple Myeloma · RECRUITING · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT05160584 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Aug 25, 2021

    Arthritis, Psoriatic · ACTIVE_NOT_RECRUITING · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

    ClinicalTrials.gov · NCT05049798 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jun 7, 2021

    Healthy · COMPLETED · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

    ClinicalTrials.gov · NCT04388501 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Mar 20, 2019

    Healthy · COMPLETED · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

    ClinicalTrials.gov · NCT03882255 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jul 11, 2017

    Renal Insufficiency · COMPLETED · sponsor: Janssen Pharmaceutica N.V., Belgium · A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

    ClinicalTrials.gov · NCT03189498 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources